peripheral neuropathy; broken bones after a fall; headaches; cough; broken bones after a fall; lost two teeth; has joint pain; This is a spontaneous report received from a non-contactable reporter(s) (Other HCP).  A 62-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Tibia", start date: Oct2021 (unspecified if ongoing), notes: Tibia, fibula and some bones in my foot; "fibula", start date: Oct2021 (unspecified if ongoing), notes: Tibia, fibula and some bones in my foot; "some bones in my foot", start date: Oct2021 (unspecified if ongoing), notes: Tibia, fibula and some bones in my foot; "bad bronchitis" (unspecified if ongoing), notes: But she said it sounds like I got bad bronchitis.; "I'm tired of being a frog" (unspecified if ongoing), notes: said, I'm tired of being a frog.; "Migraines" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Botox for Migraines, notes: Botox for my migraines. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete, Manufacturer: Unknown), for COVID-19 immunization, reaction(s): "COVID-19". The following information was reported: NEUROPATHY PERIPHERAL (medically significant), outcome "unknown", described as "peripheral neuropathy"; FRACTURE (medically significant), FALL (non-serious), outcome "unknown" and all described as "broken bones after a fall"; HEADACHE (non-serious), outcome "unknown", described as "headaches"; COUGH (non-serious), outcome "unknown"; TOOTH LOSS (non-serious), outcome "unknown", described as "lost two teeth"; ARTHRALGIA (non-serious), outcome "unknown", described as "has joint pain". The patient underwent the following laboratory tests and procedures: Electromyogram: They found no conduction, notes: lousy electromyogram. Therapeutic measures were taken as a result of cough.  Clinical course: Age/Date of Birth: 60-64 Years, Pfizer Suspect Drug Name: COVID vaccine, Azithromycin, Prevnar. The patient called the supervisor, and her message says she will call her within forty-eight hours, and it has been like three weeks since she has not called me yet. Patient was keep telling the nurses she needs her flu shot, second COVID booster and need my Prevnar twenty booster and she have not gotten any of the three yet, and they waited so long to give me the first COVID booster. Adverse event(s)/product complaint details: Patient caught COVID after vaccine, also has peripheral neuropathy, headaches, cough, broken bones after a fall, has joint pain, lost two teeth. She got a lousy electromyogram. They found no conduction, for severe peripheral neuropathy. The last time they tried to do it took two days because the, the test hurt so bad. This test, she layed down, it was a nice picture. Severe nerve damage you lose the sensation sometimes. And then she stuck the needle in the bottom of my foot, and patient did not feel nothing. She's like you have no nerve conduction. The patient having a headache. She was not happy with where she was living. She wants to go to her own apartment. A cough, terrible cough, ENT put me on it's the two pills one day and then one pill for Z-Pak. She put me on one. As soon as she finished that one, she got to start another one. But she said it sounds like she got bad bronchitis. She was tired of being a frog. Tibia, fibula, and some bones in my foot. That was in last October.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the available information in the case, the causal association between the events 'peripheral neuropathy', 'fracture' and the suspect drug BNT162B2 cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.